Folic Acid
FDA-approved product (injectable, injection), marketed as Folic Acid, Folicet, Folvite and 1 more.
- Registered studies
- 50+
- Lab records
- 3
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acne
- Anemia
- Anemia (phenotype)
- Chronic kidney disease
- Chronic renal failure syndrome
- Depressive disorder
- Folate deficiency
- Iron deficiency anemia
- Major depressive disorder
- Osteoporosis
- Type 2 diabetes mellitus
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Folic acid and derivatives; Other diagnostic agents
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli87.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae47.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- E. coli: measured active in 3 of 3 lab records
Show the 3 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Folic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents61.4% AI-predicted activityagainst E. coli1 registered study
Registered studies
A registration describes a study; it does not establish a positive result.
Oral Iron for the Management of Iron Deficiency Anemia in SGLT2i-Treated Heart Failure Patients
NCT07708025 · start 2025-09-20
Registered record
- Registry ID
- NCT07708025
- Conditions
- Heart Failure; Anemia
- Interventions
- Oral iron supplementation
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2025-09-20
- Completion
- 2026-03-15
- Enrolment
- 55
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart Failure; AnemiaInterventionOral iron supplementationPhasePhase 3Registry statusCompletedThe Benefit in Terms of Improvement in Haemoglobin Level at 6 Months in Premature Babies Receiving Alternate Iron Substitution 4 Times a Week Compared to a Daily Substitution
NCT06624709 · start 2024-11-02
Registered record
- Registry ID
- NCT06624709
- Conditions
- Premature Birth
- Interventions
- Iron Supplement
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2024-11-02
- Completion
- 2027-05
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPremature BirthInterventionIron SupplementPhaseNot applicableRegistry statusRecruitingA Novel Iron-Based Supplement for Athletes Aged 14-17
NCT06338787 · start 2024-06-17
Registered record
- Registry ID
- NCT06338787
- Conditions
- Iron Deficiencies
- Interventions
- FeSC
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Active not recruiting
- Start
- 2024-06-17
- Completion
- 2025-12
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIron DeficienciesInterventionFeSCPhaseNot applicableRegistry statusActive not recruitingEffects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women
NCT06116669 · start 2023-11-01
Registered record
- Registry ID
- NCT06116669
- Conditions
- Iron Deficiency Anemia
- Interventions
- Iron supplementation; MenACWY vaccine; COVID-19 vaccine; Placebo; Typhim Vi vaccine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2023-11-01
- Completion
- 2024-12-31
- Enrolment
- 180
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIron Deficiency AnemiaInterventionIron supplementation; MenACWY vaccine; COVID-19 vaccine; Placebo +1 morePhaseNot applicableRegistry statusUnknownEndoscopic Evaluation for Iron Deficiency Anemia in Patients on Antithrombotic Therapy
NCT07089030 · start 2023-06-06
Registered record
- Registry ID
- NCT07089030
- Conditions
- Obscure Gastrointestinal Bleeding; Iron-Deficiency Anemia; Antithrombotic Therapy
- Interventions
- Standard endoscopic evaluation; Conservative Medical Management
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2023-06-06
- Completion
- 2026-06-06
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionObscure Gastrointestinal Bleeding; Iron-Deficiency Anemia; Antithrombotic TherapyInterventionStandard endoscopic evaluation; Conservative Medical ManagementPhaseNot applicableRegistry statusRecruitingEffect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients
NCT06115421 · start 2023-05-24
Registered record
- Registry ID
- NCT06115421
- Conditions
- Anemia in Dialysis-dependent CKD Patients
- Interventions
- Roxadustat
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2023-05-24
- Completion
- 2025-01-30
- Enrolment
- 72
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnemia in Dialysis-dependent CKD PatientsInterventionRoxadustatPhasePhase 4Registry statusCompletedThe Effect of Multiple Micronutrient Supplements in Reducing Anemia in Women of Reproductive Age
NCT05682261 · start 2023-03-23
Registered record
- Registry ID
- NCT05682261
- Conditions
- Anemia
- Interventions
- UNIMMAP-MMS; IFA; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2023-03-23
- Completion
- 2023-10-17
- Enrolment
- 265
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnemiaInterventionUNIMMAP-MMS; IFA; PlaceboPhaseNot applicableRegistry statusCompletedCross-over Study to Evaluate the Rate and the Extent of Iron Absorption of an ODF Iron Supplement vs an Iron Supplement in Capsules
NCT05660200 · start 2022-11-25
Registered record
- Registry ID
- NCT05660200
- Conditions
- Iron-deficiency
- Interventions
- IBSA Iron ODF; SiderAL® FORTE
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-11-25
- Completion
- 2022-12-31
- Enrolment
- 9
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIron-deficiencyInterventionIBSA Iron ODF; SiderAL® FORTEPhaseNot applicableRegistry statusCompletedIron Supplementation for Geriatric Hip Fractures
NCT05489952 · start 2022-09-15
Registered record
- Registry ID
- NCT05489952
- Conditions
- Hip Fractures; Fragility Fracture; Osteoporotic Fractures
- Interventions
- iron sucrose and ferrous lactate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2022-09-15
- Completion
- 2025-08-15
- Enrolment
- 444
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHip Fractures; Fragility Fracture; Osteoporotic FracturesInterventioniron sucrose and ferrous lactatePhasePhase 4Registry statusUnknownSteroids vs Placebo in Treatment of Tuberculous Lymphadenitis
NCT06236152 · start 2022-07-01
Registered record
- Registry ID
- NCT06236152
- Conditions
- Tuberculous Lymphadenitis, Cervical
- Interventions
- Ferrous sulfate; Deltacortril
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-07-01
- Completion
- 2023-08-15
- Enrolment
- 140
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculous Lymphadenitis, CervicalInterventionFerrous sulfate; DeltacortrilPhaseNot applicableRegistry statusCompletedEfficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)
NCT05226169 · start 2022-04-29
Registered record
- Registry ID
- NCT05226169
- Conditions
- Advanced Gastric Carcinoma
- Interventions
- Ferinject; Conservative management
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2022-04-29
- Completion
- 2026-11-30
- Enrolment
- 330
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Gastric CarcinomaInterventionFerinject; Conservative managementPhasePhase 3Registry statusRecruitingDefining the Serum Ferritin Concentration in Kenyan Women at Which the Body Senses Iron Depletion and Begins to Upregulate Iron Absorption
NCT05266703 · start 2022-02-18
Registered record
- Registry ID
- NCT05266703
- Conditions
- Iron-deficiency; Ferritin Threshold; Iron Absorption; Stable Iron Isotopes
- Interventions
- Isotopically labelled iron sulfate 15mg
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-02-18
- Completion
- 2023-06-30
- Enrolment
- 1,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIron-deficiency; Ferritin Threshold; Iron Absorption; Stable Iron IsotopesInterventionIsotopically labelled iron sulfate 15mgPhaseNot applicableRegistry statusCompletedEarly Iron Exposure on the Gut Microbiota in Young Infants
NCT03828708 · start 2021-09-28
Registered record
- Registry ID
- NCT03828708
- Conditions
- Infant Development
- Interventions
- Iron in infant formula
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2021-09-28
- Completion
- 2024-05
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfant DevelopmentInterventionIron in infant formulaPhaseNot applicableRegistry statusUnknownIron Infusion Into a Vein Compared to Iron Tablet Taken by Mouth for Treating Iron Deficiency Anemia in Pregnancy (IVON)
NCT04976179 · start 2021-08-09
Registered record
- Registry ID
- NCT04976179
- Conditions
- Iron Deficiency Anemia of Pregnancy
- Interventions
- Ferric carboxymaltose; Ferrous sulfate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2021-08-09
- Completion
- 2023-06-15
- Enrolment
- 1,056
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIron Deficiency Anemia of PregnancyInterventionFerric carboxymaltose; Ferrous sulfatePhasePhase 3Registry statusCompletedA Clinical Trial Assessing the Efficacy of Intravenous Iron for the Treatment of Anemia Following Cardiac Surgery
NCT04608539 · start 2021-05-21
Registered record
- Registry ID
- NCT04608539
- Conditions
- Anemia Postoperative
- Interventions
- Ferric Derisomaltose; Ferrous sulfate; normal saline
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2021-05-21
- Completion
- 2023-06-27
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnemia PostoperativeInterventionFerric Derisomaltose; Ferrous sulfate; normal salinePhasePhase 4Registry statusCompleted